KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Depreciation and Depletion (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 13 years of Depreciation and Depletion data on record, last reported at $3.3 million in Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 45.49% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $10.0 million, up 4.1%, while the annual FY2025 figure was $10.0 million, 4.1% up from the prior year.
  • Depreciation and Depletion reached $3.3 million in Q4 2025 per IONS's latest filing, up from $2.3 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $4.0 million in Q2 2021 and bottomed at $2.2 million in Q1 2025.
  • Average Depreciation and Depletion over 5 years is $3.0 million, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: tumbled 33.9% in 2023, then surged 45.49% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $3.8 million in 2021, then fell by 20.8% to $3.0 million in 2022, then decreased by 15.96% to $2.5 million in 2023, then dropped by 11.95% to $2.2 million in 2024, then soared by 45.49% to $3.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $3.3 million in Q4 2025, $2.3 million in Q3 2025, and $2.3 million in Q2 2025.